trial

Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis

NCTId NCT00449397
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 150
Sponsored by AstraZeneca
Primary completion 2006-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
150
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2003-07
Primary completion
2006-01
Eligibility
ALL · 15 Years · 25 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Gregor E Berger, MDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Linked catalysts

1
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis — primary completion2006-01

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE3
Primary Completion Date
2006-01
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
AstraZeneca
company
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Gregor E Berger, MD
person